<DOC>
	<DOCNO>NCT01380145</DOCNO>
	<brief_summary>This open-label , single-arm , pilot study recombinant MAGE-A3 protein plus immunological adjuvant AS15 ( recMAGE-A3 + AS15 ) subject symptomatic multiple myeloma complete induction therapy least Very Good Partial Response ( VGPR ) International Myeloma Working Group ( IMWG ) criterion eligible high-dose chemotherapy autologous stem cell transplant ( auto-SCT ) . The primary objective determine safety tolerability immunization administer prior stem cell mobilization multiple time stem cell reinfusion . Secondary objective assess humoral cellular immunogenicity clinical outcome immunization .</brief_summary>
	<brief_title>MAGE-A3 Protein + AS15 Consolidation Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation</brief_title>
	<detailed_description>Subjects enrol sequentially follow confirmation eligibility criterion , include International Staging System ( ISS ) stage 1 , 2 , 3 multiple myeloma MAGE-A3 tumor antigen expression . Subjects receive total 8 immunization 300 µg recMAGE-A3 + AS15 . The first immunization administer approximately 6 15 week prior auto-SCT ( Day 0 ) , subsequent immunization administer every 3 week ( ± 3 day ) start 10 day auto-SCT ( ie , Days 10 , 31 , 52 , 73 , 94 ) . Two additional immunization administer 3-month interval ( ± 7 day , ie , Days 180 270 ) . No dose adjustment allow . Platelet count must ≥ 50 x 10E9/L prior immunization , blood product transfusion permit necessary . The process auto-SCT comprise following : ( 1 ) 3 steady-state leukopheresis procedure collect freeze sufficient quantity peripheral blood mononuclear cell ( PBMCs ) , first leukopheresis perform 3 week ( ± 6 day ) first immunization ; ( 2 ) stem cell mobilization cyclophosphamide , granulocyte-colony stimulating factor ( G-CSF ) and/or plerixafor ; ( 3 ) high-dose melphalan ( total dose 200 mg/m2 ) Days -3 -1 ; ( 4 ) auto-SCT Day 0 ; ( 5 ) re-infusion thaw PBMCs Day 3 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Symptomatic multiple myeloma , ISS stage 1 , 2 3 within 12 month start therapy . 2 . Completion induction therapy VGPR , good , IMWG criterion . All induction myeloma therapy ( oral intravenous , include steroid ) must discontinue 3 week prior first immunization . Subjects need measurable disease time screen visit . 3 . Signed separate inform consent stem cell mobilization highdose chemotherapy/autoSCT , find eligible SCT standard institutional criterion . 4 . MAGEA3 expression determine immunohistochemistry ( IHC ) present bone marrow specimen plasmacytoma specimen . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . The following laboratory parameter within range specify : Neutrophil count : ≥ 1.5 x 109/L Lymphocyte count : ≥ 0.5 x 109/L Platelet count : ≥ 50 x 109/L Serum creatinine : ≤ 2 mg/dL Serum bilirubin : &lt; 1.5 x upper limit normal ( ULN ) Aspartate alanine aminotransferase ( AST ALT ) : &lt; 2 x ULN Hemoglobin : ≥ 8.0 g/dL International normalized ratio ( INR ) : ≤ 1.5 Partial thromboplastin time : ≤ 1.5 x ULN ( unless know history antiphospholipid antibody lupus anticoagulant ) 7 . Age ≥ 18 year . 8 . Able willing give valid write informed consent . 1 . Prior treatment melphalan ( Alkeran® ) , 1 cycle ( 4 day ) oral melphalan . 2 . Prior autologous allogeneic SCT . 3 . Prior immunization MAGEA3 cancertestis antigen . 4 . Concurrent malignancy , except treat nonmelanoma skin cancer cervical carcinoma situ . 5 . Known immunodeficiency , human immunodeficiency virus ( HIV ) positivity , active hepatitis B C. 6 . Known allergy history lifethreatening reaction GCSF GMCSF . 7 . History autoimmune disease ( eg. , rheumatoid arthritis , lupus ) , vitiligo , diabetes , treat thyroiditis . 8 . History severe allergic reaction vaccine unknown allergen . 9 . History myocardial infarction , angina , congestive heart failure , ventricular tachyarrhythmia , stroke transient ischemic attack within previous 6 month . 10 . Other serious illness comorbid condition ( e.g. , serious infection require antibiotic , bleed disorder , heart lung condition ) , opinion investigator , make subject inappropriate highdose melphalan autoSCT . 11 . Pregnancy breastfeed . 12 . Participation clinical trial involve another investigational agent within 4 week prior first immunization . 13 . Mental impairment may compromise ability give inform consent comply requirement study . 14 . Lack availability immunological clinical followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>MAGE-A3</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>